首页TY - JOUR T1 - Factors Influencing Disability Status at Baseline in the TOP MS Study (P05.098) JF - Neurology JO - Neurology SP - P05.098 LP - P05.098 VL - 78 IS - 1 Supplement AU - Howard Zwibel AU - Patricia Coyle AU - Merrikay Oleen-Burkey AU - Douglas Denney Y1 - 2012/04/25 UR - //www.ez-admanager.com/content/78/1_Supplement/P05.098.abstract N2 - Objective: To assess the correlation of disability status with characteristics of participants in the Therapy Optimization in MS (TOP MS) Study at baseline.Background Participants in TOP MS were being treated with disease-modifying therapies (DMT) at enrollment and self-reported a range of disability from an EDSS of 0 to 8.Design/Methods: Potential participants for the TOP MS study were identified at specialty pharmacies with medication therapy management programs.签名知情同意表交回药店学习注册生成登录指令按基准和24个月定期间隔计算,注册参赛者收到提醒回复调查自报响应直接输入研究数据库.Results:topMS全数组中平均自报EDSS为3.0+2.5残疾分数与岁数大相联(Pearson相关关系(R):313!p <.001)持续时间p <.001)自诊断时间p <.001)和DMT处理持续时间p=.04即使在控制病人年龄后,这些因素仍与残疾大相联基准残疾评分与基准疲劳强度评分(FSS)(R:545!p <.001)认知缺分(PDQ)(R:418!p < 0.001),destrucep <.0001,短格式12物理p <.001)和Miscalp.001构件评分和各类损耗时间和常用活动失能度量法(全为p.001)。 结论:TOPMS研究基准自报MS残疾度量法表现良好,不依赖病人年龄,与数例病人报告疲劳度度法、认知缺陷法、抑郁症法、生活质量法和工作常态性能法有显著关联。兹维贝尔因Serono公司和TevaNeuroscience公司的活动得到了个人补偿博士兹维贝尔接受Teva神经科学研究支持博士Coyle因Acorda解析公司、Avanir药厂、Bayer药厂公司、BiogenIdec公司、Genzyme公司、Novartis公司、Questcor公司、Roche诊断公司、Sanofi-Aventis药厂和TevaNeurosci博士Coyle以编辑身份为NEURA获得个人补偿博士Coyle从Serono公司、Novartis公司和Sanofi-Aventis药厂公司获得研究支持博士Oleen-Burkey因与Teva神经科学有关的活动而获得个人补偿博士Oleen-Burkey持有Pfizer公司和TevaNeuroscience股票和/或股票选择权博士Oleen-Burkey接受Teva神经科学研究支持博士登尼因与TevaNeuroscience Inc.咨询师Drenney从Serono Inc.Wednesday2012年4月25日14:00-9:00ER-